Publications by authors named "Remy Hanf"
Article Synopsis
- A study investigated the effectiveness of elafibranor, a medication for patients with primary biliary cholangitis (PBC) who didn't respond adequately to ursodeoxycholic acid treatment.
- In a 12-week trial with 45 participants, those taking elafibranor saw significant reductions in alkaline phosphatase (ALP) levels compared to a placebo group, with notable decreases in liver disease markers.
- The results indicated elafibranor was safe, well tolerated, and improved various markers of PBC, providing hope for better management of the condition.
Background: Non-invasive tests that can identify patients with non-alcoholic steatohepatitis (NASH) at higher risk of disease progression are lacking. We report the development and validation of a blood-based diagnostic test to non-invasively rule in and rule out at-risk NASH (defined as non-alcoholic fatty liver disease [NAFLD] activity score [NAS] ≥4 and fibrosis stage ≥2).
Methods: In this prospective derivation and global validation study, blood samples, clinical data, and liver biopsy results from three independent cohorts with suspected NAFLD were used to develop and validate a non-invasive blood-based diagnostic test, called NIS4.
Objective: Bile acids (BAs) are signaling molecules controlling lipid and glucose metabolism. Since BA alterations are associated with obesity and insulin resistance, plasma BAs have been considered candidates to predict type 2 diabetes (T2D) risk. We aimed to determine (1) the association of BAs with glucose homeostasis parameters and (2) their predictive association with the risk of conversion from prediabetes to new-onset diabetes (NOD) in a prospective cohort study.
View Article and Find Full Text PDFArticle Synopsis
- Elafibranor, an agonist for specific receptors, was tested for its safety and effectiveness in treating patients with nonalcoholic steatohepatitis (NASH) in a randomized, double-blind, placebo-controlled trial.
- The study involved 276 participants assigned to receive either 80 mg or 120 mg of elafibranor daily for 52 weeks, with evaluations occurring every two months and liver biopsies taken afterward.
- Results indicated that while there was no significant difference in the primary outcome between elafibranor and placebo groups, a higher percentage of patients in the 120 mg group experienced resolution of NASH without worsening fibrosis compared to the placebo group (19% vs. 12%, P
Article Synopsis
- GFT505 is a novel medication targeting liver receptors that showed effectiveness in reducing blood sugar levels and improving insulin sensitivity in diabetic mice.
- Unlike traditional diabetes medications like rosiglitazone, GFT505 did not cause any negative effects on heart health after long-term use in monkeys.
- Overall, GFT505 has a better safety profile and effectively addresses various aspects of type 2 diabetes without the cardiac side effects seen with other treatments.
Article Synopsis
- GFT505, a dual PPAR-α/δ agonist, was studied to see its effects on insulin sensitivity in abdominally obese, insulin-resistant males.
- Over an 8-week period, GFT505 improved both peripheral and hepatic insulin sensitivity, with significant increases in glucose infusion rates and reductions in plasma free fatty acids and triglycerides.
- The findings suggest that GFT505 is a promising drug candidate for treating type 2 diabetes and nonalcoholic fatty liver disease without safety concerns.
Article Synopsis
- Nonalcoholic fatty liver disease (NAFLD) encompasses a range of liver issues, from simple fat accumulation to advanced conditions like cirrhosis, with no current approved medication for treatment.* -
- GFT505, a dual PPAR-α/δ agonist, showed effectiveness in preclinical studies, improving liver health by reducing fat, inflammation, and fibrosis in various animal models.* -
- Clinical trials on humans with metabolic syndrome indicated that GFT505 lowered liver dysfunction markers, positioning it as a promising candidate for treating NAFLD/NASH.*
Article Synopsis
- PPAR-α is a key transcription factor that regulates lipid metabolism in various organs, including the intestine, influencing levels of HDL cholesterol and triglycerides in the body.
- The study showed that activating PPAR-α using a dual ligand called GFT505 resulted in greater increases in HDL levels and enhanced expression of HDL production genes compared to the drug fenofibrate.
- Overall, PPAR-α activation improves lipid profiles by reducing cholesterol esterification and increasing HDL secretion in the intestine, highlighting its role in managing dyslipidemia.
Safety issues and prospects for future generations of PPAR modulators.
Biochim Biophys Acta
August 2007
Because of their wide range of actions on glucose homeostasis, lipid metabolism and vascular inflammation, peroxisome proliferator-activated receptors (PPARs) are promising targets for the development of new drugs for the treatment of metabolic disorders such as diabetes, dyslipidemia and atherosclerosis. In clinical practice, PPARalpha agonists, such as the already available fibrates, improve dyslipidemia, while PPARgamma agonists, such as thiazolidinediones, improve insulin resistance and diabetes. The complementary action of simultaneous activation of each PPAR in patients suffering from metabolic syndrome and type 2 diabetes has led to new pharmacological strategies focused on the development of agonists targeting more than one receptor such as the dual PPARalpha/gamma agonists.
View Article and Find Full Text PDF